Literature DB >> 8573137

Hepatocyte growth factor-induced proliferation of primary hepatocytes is mediated by activation of phosphatidylinositol 3-kinase.

G G Skouteris1, E Georgakopoulos.   

Abstract

Primary hepatocytes respond to the proliferating signals of Hepatocyte Growth Factor (HGF) through activation of the tyrosine kinase activity of the met (p145) receptor. Addition of dHGF in hepatocyte cultures resulted in receptor phosphorylation which co-precipitated with a phosphorylated protein of 85 kDa. This protein was identified as the regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase). Co-precipitation of the PI 3-kinase regulatory subunit with the met receptor was observed only with the phosphorylated receptor. Wortmanin, which specifically inhibits PI 3-kinase, was found to abolish the hepatocyte DNA synthetic response due to stimulation with dHGF. It is suggested that the D-3-phosphorylated inositol phospholipids participate as major regulators in the growth and differentiation factor-initiated cascades, this not being restricted to primary hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573137     DOI: 10.1006/bbrc.1996.0040

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Hepatocyte growth factor/scatter factor-induced intracellular signalling.

Authors:  K A Stuart; S M Riordan; S Lidder; L Crostella; R Williams; G G Skouteris
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

2.  Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse.

Authors:  N J Kerouz; D Hörsch; S Pons; C R Kahn
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

3.  PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.

Authors:  Xin He; Zhenqi Zhu; Carla Johnson; John Stoops; Amanda E Eaker; William Bowen; Marie C DeFrances
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 4.  Physiological Signaling and Structure of the HGF Receptor MET.

Authors:  Gianluca Baldanzi; Andrea Graziani
Journal:  Biomedicines       Date:  2014-12-31

5.  Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.

Authors:  Fengfeng Wang; Fei Meng; Sze Chuen Cesar Wong; William C S Cho; Sijun Yang; Lawrence W C Chan
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.